TORC News and Press, resTORbio Inc. From 04/30/20

NEW YORK, NY / ACCESSWIRE / April 30, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the...

BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of its employees, stockholders, and other meeting participants, the company has changed the ...

NEW YORK , April 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between resTORbio, Inc. (NASDAQ: TORC) and Adicet Bio, Inc. is fair to resTORbio shareholders. On behalf of resTORbio shareholders, Halper Sade...

Spark Networks SE (NYSEMKT: LOV ) +38%  on 2H results . More news on: Spark Networks SE, Chimerix, Inc., resTORbio, Inc., Stocks on the move, , Read more ...

Nano cap resTORbio (NASDAQ: TORC ) has agreed to merge with privately held off-the-shelf T cell therapy developer Adicet Bio in an all-stock transaction. More news on: resTORbio, Inc., Healthcare stocks news, Merger & acquisition news, Stocks on the move, Read more ...

Combined Company to Focus on Adicet’s Technology and Continue Operations as “Adicet Bio” Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20 for treatment of non-Hodgkin’s l...

Aytu BioScience (NASDAQ: AYTU ) has begun shipping its rapid antibody blood test for COVID-19. Shares up  8%  premarket. More news on: Aytu BioScience, Inc., Stryker Corporation, Novartis AG, Healthcare stocks news, Stocks on the move, Read more ...

BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally administered, small molecule product candidate that is a potent inhibitor of target of rapamycin com...

resTORbio (NASDAQ: TORC ): Q4 GAAP EPS of -$0.79 misses by $0.16 . More news on: resTORbio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BOSTON, March 12, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results...